A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors

This study tests a new drug called KIVU-107 — a type of antibody-drug conjugate (a targeted therapy that delivers a cell-killing payload directly to cancer cells) — in people with advanced or metastatic solid tumors that have not responded to standard treatments. **You may be eligible if...** - You are 18 or older with a confirmed advanced or metastatic solid tumor - Your cancer is resistant to standard therapy or no standard therapy is available - You have adequate bone marrow, kidney, and liver function - You have measurable disease on scans (per RECIST criteria) - Your general health is good (ECOG 0 or 1) and life expectancy is at least 3 months **You may NOT be eligible if...** - You have previously received any antibody-drug conjugate with a topoisomerase 1 inhibitor payload - You have received any PTK7-targeted therapy before - You have active hepatitis B, hepatitis C, or HIV infection - You have a history of interstitial lung disease - You have had major surgery, radiation, or systemic cancer treatment within 3 weeks of starting the study Talk to your doctor to see if this trial is right for you.